TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR
HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN
REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING
2013-2021

a 2023

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

BORJAS, Olmedo, X Calvet CALVO, E Gené TOUS, D S BORDIN, I VOYNOVA et. al.

Základní údaje

Originální název

TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021

Autoři

BORJAS, Olmedo, X Calvet CALVO, E Gené TOUS, D S BORDIN, I VOYNOVA, M CASTRO-FERNANDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, Á PÉREZ-AÍSA, A J LUCENDO, L RODRIGO, A Silkanovna SARSENBAEVA, I B KHLINOV, G FADIEIENKO, O ZAYTSEV, Á LANAS, S J MARTÍNEZ-DOMÍNGUEZ, E Alfaro ALMAJANO, L JONAITIS, Ó NUÑEZ, R PELLICANO, L HERNÁNDEZ, O GRIDNYEV, J JUOZAS, A GASBARRINI, D BOLTIN, Y NIV, G BABAYEVA, R MARCOS-PINTO, B TEPES, M VENERITO, V PAPP, F LERANG, M LEJA, P S PHULL, W MARLICZ, M DOULBERIS, S M SMITH, V MILIVOJEVIC, Lumír KUNOVSKÝ, A TONKIĆ, T MATYSIAK-BUDNIK, H SIMSEK, A CANO-CATALÀ, L MOREIRA, P PARRA, O P NYSSEN, F MÉGRAUD, MORAIN a J P GISBERT

Vydání

31st United European Gastroenterology Week 2023, 2023

Další údaje

Typ výsledku

Konferenční abstrakt

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 6.000 v roce 2022

Organizační jednotka

Lékařská fakulta

ISSN

Změněno: 18. 12. 2023 09:33, Mgr. Tereza Miškechová

Anotace

V originále

Contact E-Mail Address: drapereza@hotmail.com Introduction: Bismuth quadruple therapy (BQT) including bismuth, a proton pump inhibitor (PPI) and two antibiotics has been shown to be a very effective treatment for Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Bismuth prescriptions seem to be increasing in recent years. Aims & Methods: To describe the use, effectiveness, and safety of BQT in Europe and the evolution of prescriptions as part of the European Registry on Helicobacter pylori management (Hp-EuReg). All patients who had received BQT in a 9-year period were included. The thirty-one countries participating in the Hp-EuReg been clustered in previous studies in five main regions based both on their geographical situation and the gross domestic product per capita (North, Centre, Est, South-Est, South-West). Data on the prescribed schedules, previous eradication attempts, effectiveness and the incidence of adverse events was analysed. A time trend analysis of the different BQT treatment prescriptions was likewise performed. Effectiveness was defined by a modified intention-totreat (mITT) analysis. A multivariate analysis was performed to determine the variables predicting treatment effectiveness. Results: Of the 49,690 patients included in the Hp-EuReg, 15,582 (31%) had received BQT. BQT use increased from 8.6% to 39% during the study period. Forty-six different schedules were used, of which 8 were administered to more than 100 patients. Single-capsule BQT (ScBQT) containing bismuth, metronidazole and tetracycline plus a PPI was the most used therapy (43%). In naïve patients, the following BQTs obtained over 90% effectiveness: those using tetracycline and metronidazole, either drugs prescribed separately for 14 days, or as 10-day ScBQT; and those using amoxicillin either with clarithromycin or metronidazole, both for 14 days. ScBQT was the only schedule achieving optimal cure rates in all the geographical areas. Standard- or high-dose PPIs, prescriptions of 10-14 days and the schedule type are significantly related to higher cure rates in the multivariate analysis.

Citovat

@proceedings{2351139,
   author = {Borjas, Olmedo and Calvo, X Calvet and Tous, E Gené and Bordin, D S and Voynova, I and CastroandFernandez, M and PabónandCarrasco, M and KecoandHuerga, A and PérezandAísa, Á and Lucendo, A J and Rodrigo, L and Sarsenbaeva, A Silkanovna and Khlinov, I B and Fadieienko, G and Zaytsev, O and Lanas, Á and MartínezandDomínguez, S J and Almajano, E Alfaro and Jonaitis, L and Nuñez, Ó and Pellicano, R and Hernández, L and Gridnyev, O and Juozas, J and Gasbarrini, A and Boltin, D and Niv, Y and Babayeva, G and MarcosandPinto, R and Tepes, B and Venerito, M and Papp, V and Lerang, F and Leja, M and Phull, P S and Marlicz, W and Doulberis, M and Smith, S M and Milivojevic, V and Kunovský, Lumír and Tonkić, A and MatysiakandBudnik, T and Simsek, H and CanoandCatalà, A and Moreira, L and Parra, P and Nyssen, O P and Mégraud, F and Morain, and Gisbert, J P},
   booktitle = {31st United European Gastroenterology Week 2023},
   title = {TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021},
   url = {https://onlinelibrary.wiley.com/toc/20506414/2023/11/S8},
   year = {2023}
}

TY  - CONF
ID  - 2351139
AU  - Borjas, Olmedo - Calvo, X Calvet - Tous, E Gené - Bordin, D S - Voynova, I - Castro-Fernandez, M - Pabón-Carrasco, M - Keco-Huerga, A - Pérez-Aísa, Á - Lucendo, A J - Rodrigo, L - Sarsenbaeva, A Silkanovna - Khlinov, I B - Fadieienko, G - Zaytsev, O - Lanas, Á - Martínez-Domínguez, S J - Almajano, E Alfaro - Jonaitis, L - Nuñez, Ó - Pellicano, R - Hernández, L - Gridnyev, O - Juozas, J - Gasbarrini, A - Boltin, D - Niv, Y - Babayeva, G - Marcos-Pinto, R - Tepes, B - Venerito, M - Papp, V - Lerang, F - Leja, M - Phull, P S - Marlicz, W - Doulberis, M - Smith, S M - Milivojevic, V - Kunovský, Lumír - Tonkić, A - Matysiak-Budnik, T - Simsek, H - Cano-Català, A - Moreira, L - Parra, P - Nyssen, O P - Mégraud, F - Morain,
AU  - Gisbert, J P
PY  - 2023
TI  - TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021
UR  - https://onlinelibrary.wiley.com/toc/20506414/2023/11/S8
N2  - Contact E-Mail Address: drapereza@hotmail.com Introduction: Bismuth quadruple therapy (BQT) including bismuth, a proton pump inhibitor (PPI) and two antibiotics has been shown to be a very effective treatment for Helicobacter pylori infection even in areas of high bacterial antibiotic resistance. Bismuth prescriptions seem to be increasing in recent years. Aims & Methods: To describe the use, effectiveness, and safety of BQT in Europe and the evolution of prescriptions as part of the European Registry on Helicobacter pylori management (Hp-EuReg). All patients who had received BQT in a 9-year period were included. The thirty-one countries participating in the Hp-EuReg been clustered in previous studies in five main regions based both on their geographical situation and the gross domestic product per capita (North, Centre, Est, South-Est, South-West). Data on the prescribed schedules, previous eradication attempts, effectiveness and the incidence of adverse events was analysed. A time trend analysis of the different BQT treatment prescriptions was likewise performed. Effectiveness was defined by a modified intention-totreat (mITT) analysis. A multivariate analysis was performed to determine the variables predicting treatment effectiveness. Results: Of the 49,690 patients included in the Hp-EuReg, 15,582 (31%) had received BQT. BQT use increased from 8.6% to 39% during the study period. Forty-six different schedules were used, of which 8 were administered to more than 100 patients. Single-capsule BQT (ScBQT) containing bismuth, metronidazole and tetracycline plus a PPI was the most used therapy (43%). In naïve patients, the following BQTs obtained over 90% effectiveness: those using tetracycline and metronidazole, either drugs prescribed separately for 14 days, or as 10-day ScBQT; and those using amoxicillin either with clarithromycin or metronidazole, both for 14 days. ScBQT was the only schedule achieving optimal cure rates in all the geographical areas. Standard- or high-dose PPIs, prescriptions of 10-14 days and the schedule type are significantly related to higher cure rates in the multivariate analysis.
ER  -

BORJAS, Olmedo, X Calvet CALVO, E Gené TOUS, D S BORDIN, I VOYNOVA, M CASTRO-FERNANDEZ, M PABÓN-CARRASCO, A KECO-HUERGA, Á PÉREZ-AÍSA, A J LUCENDO, L RODRIGO, A Silkanovna SARSENBAEVA, I B KHLINOV, G FADIEIENKO, O ZAYTSEV, Á LANAS, S J MARTÍNEZ-DOMÍNGUEZ, E Alfaro ALMAJANO, L JONAITIS, Ó NUÑEZ, R PELLICANO, L HERNÁNDEZ, O GRIDNYEV, J JUOZAS, A GASBARRINI, D BOLTIN, Y NIV, G BABAYEVA, R MARCOS-PINTO, B TEPES, M VENERITO, V PAPP, F LERANG, M LEJA, P S PHULL, W MARLICZ, M DOULBERIS, S M SMITH, V MILIVOJEVIC, Lumír KUNOVSKÝ, A TONKI$\backslash$'C, T MATYSIAK-BUDNIK, H SIMSEK, A CANO-CATALÀ, L MOREIRA, P PARRA, O P NYSSEN, F MÉGRAUD, MORAIN a J P GISBERT. TIME TRENDS AND EFFECTIVENESS OF BISMUTH TREATMENT FOR HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON HELICOBACTER PYLORI MANAGEMENT (HP-EUREG) DURING 2013-2021. In \textit{31st United European Gastroenterology Week 2023}. 2023. ISSN~2050-6406.

Podrobný výpis o publikaci